Back to results
US 10,206,999 B2Granted
Antibodies against LIF and uses thereof
AssigneesMosaic Biomedicals, S.L., Fundacio Privada Institut d'Investigacio Oncologica de Vall Hebron, Fundació Privada Institució Catalana de Recerca | Estudis Avançats
InventorsJoan Seoane Suarez, Judit Anido Folgueira
Life of this patent
Estimating the term…
Abstract
Described herein are antibodies that target Leukemia Inhibitory Factor (LIF). Also described herein are uses of these antibodies for the treatment of cancer.
Claims17
A recombinant antibody that specifically binds Leukemia Inhibitory Factor (LIF), the antibody comprising:
- a) a heavy chain complementarity determining region 1 (VH-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:
- 2 (GFTFSHAW);
- b) a heavy chain complementarity determining region 2 (VH-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:
- 10 (IKAKSDDYAT);
- c) a heavy chain complementarity determining region 3 (VH-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:
- 15 (TCWEWDLDF);
- d) a light chain complementarity determining region 1 (VL-CDR1) comprising the amino acid sequence set forth in SEQ ID NO:
- 22 (QSLLDSDGHTY);
- e) a light chain complementarity determining region 2 (VL-CDR2) comprising the amino acid sequence set forth in SEQ ID NO:
- 26 (SVS);
- and
- f) a light chain complementarity determining region 3 (VL-CDR3) comprising the amino acid sequence set forth in SEQ ID NO:
- 29 (MQATHAPPYT).
10 more elements
Dependencies are inferred from the claim text.